MapLight Therapeutics, Inc. (MPLT) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Paul Matteis.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Paul Matteis has given his Buy rating due to a combination of factors that highlight MapLight Therapeutics, Inc. as a promising investment opportunity. The company is positioned as a potential second-mover in the muscarinic space, which, despite the slower than expected launch of Cobenfy, still presents a substantial revenue opportunity. MPLT’s drug candidate, ML-007C-MA, is designed to leverage insights from previous muscarinic drugs while offering potential differentiation through more convenient dosing and improved tolerability.
Additionally, the upcoming BMY ADEPT-2 readout is a significant event for the sector, with low market expectations creating a scenario where the risk/reward is skewed positively for MPLT. Even if the study results are negative, the comprehensive data will be crucial for understanding broader implications. Furthermore, MPLT is conducting two phase 2 trials for ML-007C-MA in schizophrenia and ADP, with promising data expected in the latter half of 2026 and 2027. The company’s financial position is strong, with funding secured through these key readouts, and an additional program in autism spectrum disorder that could enhance their model further.
In another report released today, Jefferies also initiated coverage with a Buy rating on the stock with a $32.00 price target.